Acutaas Chemicals Limited has issued the notice for its 19th Annual General Meeting (AGM), scheduled for September 24, 2026. The meeting will address the final dividend for FY26, board appointments, and significant related party transactions.

The company confirmed that dividend payments will be subject to withholding tax as per the Income-tax Act, 2025, effective from April 1, 2026. The record date for determining dividend entitlement remains September 17, 2026. If declared, the dividend will be paid within 30 days of the AGM.

Tax Deduction Guidelines

For resident individual shareholders, TDS is levied at 10% if a valid Permanent Account Number (PAN) is registered. The rate rises to 20% under Section 397(2) of the Act if PAN details are missing or not linked to Aadhaar. No tax is deducted if the total dividend received does not exceed ₹10,000 or if shareholders submit Form 121 meeting eligibility conditions.

Resident non-individuals, including insurance companies and mutual funds, can claim exemption by providing self-declarations and relevant registration certificates. Non-resident shareholders are subject to a withholding tax of 20% plus applicable surcharge and cess. However, they may avail beneficial rates under Double Taxation Avoidance Agreements (DTAA) by submitting Form 41, a Tax Residency Certificate, and other required documents.

Shareholders must submit necessary documents, such as Form 121 or DTAA certificates, by September 15, 2026. Late submissions will result in TDS being deducted at the higher statutory rate. Shareholders can upload documents via the Registrar and Transfer Agent’s portal or email them to the designated address.

Capital Expenditure Plans

During the board meeting held on August 22, 2026, Acutaas Chemicals approved a capital expenditure plan of up to ₹212 crore. The investment aims to establish manufacturing facilities for electronic grade chemicals in Gujarat. The project targets a production capacity of up to 81,000 metric tonnes per annum.

The company plans to complete this capacity addition by the end of FY27-28. Financing for the outlay will come from internal accruals, bank finance, or other permissible methods. The expansion may be undertaken by the parent company or through its Indian subsidiaries.

Board and Governance Updates

The board recommended the re-appointment of Mr. Ram Mohan Lokhande as Whole Time Director and Mrs. Anita Bandyopadhyay as Non-Executive Independent Director. Both appointments are for five-year terms starting February 8, 2027, subject to shareholder approval at the AGM. Mr. Chetankumar C. Vaghasia also retires by rotation and offers himself for re-appointment.

Additionally, the board approved extending the benefits of the Ami Organics Employees Stock Option Scheme 2023 to eligible employees of the company’s Indian subsidiaries. This proposal also requires shareholder approval at the AGM.

Related Party Transactions and Loans

The AGM notice seeks approval for material related party transactions with subsidiary Acutaas Chemicals Electrolytes Private Limited (ACEPL). Since May 19, 2026, Acutaas Chemicals holds 90% equity in ACEPL following a preferential issue. The company seeks omnibus approval for transactions up to ₹2,900 million until the next AGM.

Furthermore, the company seeks special resolution approval to advance loans or provide guarantees to ACEPL up to ₹1,000 million outstanding at any point in time. As of June 30, 2026, ₹142.4 million was outstanding on account of loans given to ACEPL. These facilities are intended for ACEPL's principal business activities, including capital expenditure and working capital requirements.

Dividend and AGM Details

The company published advertisements in the Financial Express (English and Gujarati editions) on August 24, 2026, to notify shareholders of the upcoming event. The dividend intimation was issued pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE00FF01025/86ac93cb-9b07-4c1a-911a-765a79f90472.pdf

Acutaas Chemicals Limited (formerly Ami Organics Limited) delivered a landmark FY2026, with consolidated revenue from operations rising 33% year-on-year to ₹13,394 Mn and profit after tax surging 122% to ₹3,564 Mn.

The Gujarat-headquartered specialty chemicals company filed its Annual Report for FY2025-26 on August 29, 2026, ahead of its 19th Annual General Meeting scheduled for September 24, 2026. The results reflect broad-based growth across its pharmaceutical intermediates and emerging specialty chemicals verticals, with EBITDA more than doubling to ₹4,804 Mn and EBITDA margin expanding sharply to 35.9% from 23.0% in FY2025.

Key Financial Highlights

The following table summarises consolidated financial performance across the last three fiscal years.

*Adjusted for exceptional items. RoE and RoCE adjusted for cash and cash equivalents, exceptional items, and CWIP.

The Advanced Pharmaceutical Intermediates segment, the company's largest, grew 37.5% year-on-year to ₹11,741 Mn, driven primarily by the CDMO business. The Specialty Chemicals segment registered growth of 8.0%, achieving revenue of ₹1,652 Mn. Exports contributed approximately 77% of total revenue in FY2026.

Business Segment Performance

Pharmaceutical Intermediates and CDMO

The pharmaceutical intermediates business, which commands 50–90% global market share in key molecules, served 160+ customers across 25+ countries and 17+ therapeutic areas from two manufacturing facilities. During FY2026, four additional CDMO products were successfully validated, adding to the company's anchor innovator contract. The Ankleshwar manufacturing facility received Good Manufacturing Practices (GMP) certification from the Pharmaceutical and Medical Devices Agency, Japan (PMDA), without any critical or major observations.

Battery Chemicals

Phase 1 of the battery chemicals project at Jhagadia, Gujarat, was inaugurated on January 19, 2026, establishing annual production capacity of 2,000 MTPA each for Vinylene Carbonate (VC) and Fluoroethylene Carbonate (FEC). Acutaas is India's first electrolyte additives manufacturer. The entire commercialised capacity is covered by long-term customer contracts for the next three years. FY2027 is expected to be the first year of revenue contribution from this segment.

Semiconductor Chemicals

The semiconductor chemicals business, anchored by Baba Fine Chemicals — India's only manufacturer of photoresist chemicals — generated ₹157 Mn in revenue. During FY2026, approximately ₹2,000 Mn was invested in Indichem Inc., a joint venture with South Korea's J & Materials Co. Ltd., to establish an advanced semiconductor chemicals facility in Gongju, South Korea. The R&D centre at this facility is already operational and supplying samples to prospective customers. The manufacturing facility is under construction and expected to be on stream in H2 CY26.

Capital Allocation and Balance Sheet

Capex deployed in FY2026 stood at ₹1,950 Mn, directed primarily towards the Jhagadia battery chemicals project, a new pilot plant, and routine maintenance. The company's multi-year capex programme spanning FY2023 to FY2030 totals ₹10,000+ Mn across five pillars.

Net cash and cash equivalents stood at ₹1,983 Mn as on March 31, 2026. The debt-equity ratio was 0.02x. Working capital days moved from 114 days to 120 days. RoCE reached a company record of 39.3% in FY2026, up from 19.1% in FY2025.

Dividend and Corporate Actions

The Board of Directors recommended a final dividend of ₹2.50 per equity share of face value ₹5 each (50% of face value) for FY2025-26, subject to shareholder approval at the 19th AGM. The total dividend outgo, if declared, would amount to ₹204.68 Mn. The record date for dividend eligibility is September 17, 2026.

During the year, the company completed its rebranding from Ami Organics Limited to Acutaas Chemicals Limited, effective May 15, 2025. Subsidiary names were also aligned: Baba Advance Materials Limited was renamed Acutaas Advance Material Limited, and Ami Organics Electrolytes Private Limited was renamed Acutaas Chemicals Electrolytes Private Limited.

ESG and Operational Highlights

Acutaas received the EcoVadis Platinum rating in August 2025, placing it in the top 1% of companies assessed globally. The company also received the Responsible Care certification from the Indian Chemical Council and was recognised as a Great Place To Work. Renewable energy capacity installed stands at 16 MW, with solar power meeting 52% of electricity requirements at the Ankleshwar and Jhagadia facilities. Total waste recycled reached 85% through GPCB-approved recyclers, with zero safety-related incidents and zero regulatory incidents reported for FY2026.

The R&D team comprises 130+ professionals including 30+ PhDs, supported by a DSIR-approved centre spanning 2,200 sq. mt. The company holds 29 process patents (10 granted, 9 published, 10 under publication).